ES2421720T3 - Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican - Google Patents

Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican

Info

Publication number
ES2421720T3
ES2421720T3 ES00923254T ES00923254T ES2421720T3 ES 2421720 T3 ES2421720 T3 ES 2421720T3 ES 00923254 T ES00923254 T ES 00923254T ES 00923254 T ES00923254 T ES 00923254T ES 2421720 T3 ES2421720 T3 ES 2421720T3
Authority
ES
Spain
Prior art keywords
homologues
encode
nucleic acids
necrosis factor
tumor necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00923254T
Other languages
English (en)
Inventor
Audrey Goddard
James Pan
Minhong Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2421720T3 publication Critical patent/ES2421720T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

Anticuerpo aislado que se une específicamente a un polipéptido DNA101848 que comprende los residuos deaminoácidos 1 a 297 de la SEQ ID NO: 6 y es capaz de inhibir la unión de EDA-A2 a dicho polipéptido DNA101848.
ES00923254T 1999-04-12 2000-04-12 Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican Expired - Lifetime ES2421720T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12884999P 1999-04-12 1999-04-12
PCT/US2000/009699 WO2000061757A1 (en) 1999-04-12 2000-04-12 Tumor necrosis factor homologs and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ES2421720T3 true ES2421720T3 (es) 2013-09-05

Family

ID=22437287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00923254T Expired - Lifetime ES2421720T3 (es) 1999-04-12 2000-04-12 Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican

Country Status (8)

Country Link
US (4) US6534061B1 (es)
EP (1) EP1169448B1 (es)
JP (2) JP4716578B2 (es)
AU (1) AU779402B2 (es)
CA (1) CA2365913C (es)
ES (1) ES2421720T3 (es)
IL (2) IL145676A0 (es)
WO (1) WO2000061757A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020143147A1 (en) * 1998-07-13 2002-10-03 Murphy Erin E. Mammalian genes; related reagents
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
WO2001030850A1 (en) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Umlr polypeptides
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
WO2003013583A1 (en) * 2001-08-10 2003-02-20 Genset S.A. Faxigen agonists and antagonists in the treatment of metabolic disorders
US20030059889A1 (en) * 2001-09-05 2003-03-27 Bodian Dale Lesley Tumor necrosis factor receptor related protein-1 gene and protein
EP1558278B1 (en) * 2002-10-11 2009-09-02 ZymoGenetics, Inc. Production of homotrimeric fusion proteins
WO2005018571A2 (en) * 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
CA2547459C (en) * 2003-11-30 2013-10-08 Yeda Research And Development Co. Ltd Modulators of nik-siva complex formation for treating immune disorders
EP1846034A4 (en) 2005-02-02 2010-11-10 Uab Research Foundation AGENTS AND METHODS OF REDUCING THE RESISTANCE TO APOPTOSIS INDUCING DEATH RECEPTOR AGONISTS
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
BRPI1006141B8 (pt) * 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
DK2462165T3 (en) 2009-08-03 2016-08-29 Univ Miami Method for in vivo proliferation of regulatory T cells
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ ＴＬ１Ａ−Ｉｇ融合タンパク質を用いる制御性Ｔ細胞の制御のための組成物及び方法
US20220251548A1 (en) * 2019-06-06 2022-08-11 Regents Of The University Of Minnesota Methods for producing a library of biological molecules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
GB9625422D0 (en) 1996-12-06 1997-01-22 Smith & Nephew Adhesives
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
IL135051A0 (en) 1997-10-10 2001-05-20 Genentech Inc Apo-3 ligand polypeptide
EP1093516A2 (en) * 1998-07-06 2001-04-25 Schering Corporation Mammalian genes; dendritic cell prostaglandin-like transporter (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods
US20020143147A1 (en) * 1998-07-13 2002-10-03 Murphy Erin E. Mammalian genes; related reagents
US20060205034A1 (en) * 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
JP2004516227A (ja) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof

Also Published As

Publication number Publication date
EP1169448B1 (en) 2013-05-08
AU779402B2 (en) 2005-01-20
JP4716578B2 (ja) 2011-07-06
IL145676A0 (en) 2002-06-30
US6534061B1 (en) 2003-03-18
IL145676A (en) 2010-02-17
JP2011097953A (ja) 2011-05-19
US20120178163A1 (en) 2012-07-12
US20080305996A1 (en) 2008-12-11
EP1169448A1 (en) 2002-01-09
US7198913B2 (en) 2007-04-03
AU4341200A (en) 2000-11-14
WO2000061757A1 (en) 2000-10-19
CA2365913C (en) 2015-03-03
US20030092044A1 (en) 2003-05-15
CA2365913A1 (en) 2000-10-19
JP2002541806A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
ES2421720T3 (es) Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican
RS50728B (sr) Nukleinske kiseline i polipeptidi novog receptora
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
DE69738432D1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
UY28641A1 (es) Anticuerpos
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE488249T1 (de) Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
DE69836823D1 (de) Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
Lund et al. The human chromosomal protein HMG I contains two identical palindrome amino acid sequences
ATE323764T1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
PT833917E (pt) Moleculas polipeptidicas do estadio pre-eritrocitario do paludismo
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
DE69732363D1 (de) HUMANES THYMOSIN beta 15 GEN,PROTEIN UND DESSEN VERWENDUNGEN
PT639225E (pt) Polipeptidos e peptidos novos acidos nucleicos que codificam para aqueles e sua utilizacao na area da terapia tumoral inflamacao ou imunologia
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
DE69832299D1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
ATE180679T1 (de) Neue verbesserungen hinsichtlich der radiomarkierung von proteinen
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
ATE393224T1 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse